glp-1 receptor agonist medicines The Impact of Agonists on Sedation GLP-1 receptor agonists are promising

In a clinical trial involving individuals with established cardiovascular disease, retatrutide reduced the risk of major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death

Liraglutide, semaglutide and dulaglutide have demonstrated cardiovascular benefits, and Wegovy recently added to this evidence base: in the SELECT trial, patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo

For researchers who need pure GLP-1 agonism without confounding from GIP and glucagon pathways, semaglutide remains the better choice

Accessed 3 Nov 2025

JAMA Surg 2024;159:660-7.ArticlePubMedPMC 20

The agreement is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976